NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · IEX Real-Time Price · USD
1.460
-0.050 (-3.31%)
At close: May 1, 2024, 4:00 PM
1.500
+0.040 (2.74%)
After-hours: May 1, 2024, 7:55 PM EDT
NKGen Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
33.30M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
Dec 31, 2021 | 426.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNKGN News
- 2 days ago - NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease - GlobeNewsWire
- 6 days ago - NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit - GlobeNewsWire
- 7 days ago - NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 13 days ago - NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit - GlobeNewsWire
- 20 days ago - NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs - GlobeNewsWire
- 5 weeks ago - NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference - GlobeNewsWire
- 4 months ago - NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire